Skip to main content

Table 1 Demographic and baseline data

From: Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial

   rBet v 1-FV Comparator birch pollen depot preparation Reference group
n = 24 n = 27 n = 34
Gender (n) M/F 10/14 13/14 10/24
Age (years) Mean ± SD 41.00 ± 12.28 37.70 ± 9.83 38.38 ± 11.58
Range 20–63 22–60 23–59
Bet v 1 specific IgE at recruitment out of season (kUA/L) Mean ± SD 21.79 ± 24.96 21.28 ± 39.76 n.a.
Range 0.6–101.2 0.7–168.1
Allergic symptoms     
Conjunctivitis n (%) 24 (100 %) 27 (100 %) 34 (100 %)
Rhinitis n (%) 24 (100 %) 26 (96 %) 34 (100 %)
Cough/sibilant rhonchi n (%) 6 (25 %) 3 (11 %) 20 (59 %)
Allergic asthma n (%) 9 (38 %) 11 (41 %) 15 (44 %)
Atopic dermatitis n (%) 1 (4 %) 0 (0 %) 4 (12 %)
Duration of symptoms (years) Mean ± SD 11.75 ± 10.86 12.52 ± 9.34 14.09 ± 6.45
Range 1–43 1–33 2–26
Median SMS on 15th March first treatment yeara   3.0 3.0 5.5
  1. n.a.: not available; afirst day on which SMS data was collected